Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses
- Resource Type
- article
- Authors
- Darshan Mehta; Matthew Davis; Andrew J. Epstein; Brian Wensel; Todd Grinnell; G. Rhys Williams
- Source
- Neurology and Therapy, Vol 9, Iss 2, Pp 585-598 (2020)
- Subject
- Anti-seizure drug
Early initiation
Economic benefit
Epilepsy
Eslicarbazepine acetate
Focal seizures
Neurology. Diseases of the nervous system
RC346-429
- Language
- English
- ISSN
- 2193-8253
2193-6536
Abstract Introduction This study assessed the association between early initiation of eslicarbazepine acetate (ESL) as first-line therapy (1L cohort) or as first adjunctive regimen to either levetiracetam (LEV) or lamotrigine (LTG) (add-on cohort), and healthcare resource utilization (HCRU) and charges among adults with treated focal seizures (FS). Methods This retrospective, longitudinal cohort analysis used Symphony Health’s Integrated Dataverse (IDV®) claims data to identify patients aged ≥ 18 years with a diagnosis of FS who had a new prescription for ESL between April 2015 and June 2018. Baseline was the 90-day period immediately prior to the date of the first-dispensed claim for ESL (index date) with a follow-up of 1–4 consecutive 90-day periods. Linear regression models were estimated to assess changes in HCRU and charge outcomes. Results There were 274 and 153 patients who received ESL in the 1L cohort and add-on cohort, respectively. The 1L cohort experienced significant reductions from baseline during follow-up in all-cause inpatient (IP; P